Project Grant R01CA282785
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $583,973.00 to the Sloan-Kettering Institute for Cancer Research to investigate the role of EP300 mutations in bladder cancer pathogenesis and drug response. The key objectives are to: Study how EP300 loss-of-function mutations mediate resistance to FGFR inhibitors like erdafitinib using patient-derived bladder cancer models. Identify genomic alterations, especially EP300...
- This $2,970,010 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research conducted by Northwestern University to study the mechanisms by which somatic truncation mutations in the histone methyltransferase KMT2D (also known as MLL4) alter its subcellular localization and drive tumorigenesis in bladder cancer. The key goals are to: 1) define how MLL4 truncation and cytoplasmic relocalization impact its normal functions and...
- This $2,108,734 Project Grant was awarded on September 1, 2025 by the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to The University of Texas M.D. Anderson Cancer Center to conduct a 5-year research program focused on bladder cancer. The key objectives of this research program are: 1) Developing molecular profiles of bladder cancer evolution from field effects to aggressive disease, and investigating the role of LPAR6 and CAB39L in dysregulating urothelial...
- This Project Grant award of $543,221.00 from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) is supporting research at the Albert Einstein College of Medicine to better understand the cellular and molecular mechanisms driving lineage plasticity in basal-like breast cancer (BLBC). The key objectives are to: 1) Define the critical de-differentiated cell states involved in BLBC progression and explore strategies to target these cells for cancer...
- This Project Grant award of $631,156 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) supports research to uncover the core mechanisms driving lineage plasticity (LP) in EGFR-mutant lung adenocarcinoma (LUAD). The research aims to systematically define the epigenetic, transcriptional, and signaling alterations that facilitate the transformation of LUAD to the more aggressive small cell lung cancer (SCLC) subtype, a lethal mechanism...
- The National Cancer Institute awarded a $1,542,555 Project Grant to Sloan-Kettering Institute For Cancer Research under the Cancer Treatment Research program (CFDA 93.395). The grant will fund research from December 2022 through November 2027 to develop more effective treatments for localized bladder cancer. Specifically, the grantee will conduct genomic analyses of bladder cancer patient cohorts to validate DNA damage response mutations as predictors of sensitivity to bacillus Calmette-Guérin...
- The University of North Carolina at Chapel Hill (UNC-CH) received a $514,582 Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct research on "Targeting APOBEC3-Induced Squamous Differentiation in Bladder Cancer". The award began on March 1, 2025 and is set to conclude on February 28, 2030. The research aims to investigate the role of APOBEC3 enzymes in bladder cancer initiation and progression,...
- The National Cancer Institute (NCI) awarded a $730,400 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Sloan-Kettering Institute for Cancer Research in New York. The goal of this 5-year project is to determine how specific metabolic configurations in lung adenocarcinoma (LUAD) cancer cells support the emergence and maintenance of treatment-resistant cell states. The research team will manipulate components of the tricarboxylic acid (TCA) cycle in mouse and...
- This federal Project Grant award of $192,564 from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) supports Yale University's research to develop an innovative dual-target protein degrader that simultaneously inhibits lineage plasticity and therapy resistance drivers in metastatic castration-resistant prostate cancer (mCRPC). The research aims to overcome mCRPC's remarkable adaptability and lineage switching, which enable evasion of targeted therapies....
- This Project Grant award of $143,788 from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research on genetic dependencies in pediatric low-grade gliomas (PLGG) with KIAA1549-BRAF rearrangements. The primary goals are to understand how the KIAA1549:BRAF fusion is activated, and why the POMT complex is essential for the survival of KIAA1549:BRAF-dependent cells. The research will test hypotheses related to the role of POMT enzymatic activity,...
INVESTIGATING MECHANISMS OF TUMOR PLASTICITY IN HUMAN BLADDER CANCER - PROJECT SUMMARY/ABSTRACT THE PROGRESSION OF BLADDER CANCER FROM NON-INVASIVE TO MUSCLE INVASIVE DISEASE REPRESENTS A CRITICAL STEP THAT IS ASSOCIATED WITH ADVERSE CLINICAL OUTCOMES, YET IS POORLY UNDERSTOOD AT THE MOLECULAR LEVEL. HOWEVER, THERE IS INCREASING EVIDENCE FROM US AND OTHERS THAT PROGRESSION IS OFTEN ASSOCIATED WITH LINEAGE PLASTICITY, IN WHICH THE TUMOR PHENOTYPE UNDERGOES A SWITCH FROM A LUMINAL TO A BASAL SUBTYPE. THEREFORE, WE WILL PURSUE A COMPREHENSIVE MOLECULAR ANALYSIS OF LUMINAL-BASAL LINEAGE PLASTICITY TO ELUCIDATE THE MECHANISTIC BASIS FOR THIS PHENOTYPIC SWITCH. IN PRELIMINARY STUDIES, WE HAVE SHOWN THAT PATIENT-DERIVED BLADDER TUMOR ORGANOIDS REPRESENT A MODEL SYSTEM FOR STUDYING TUMOR PLASTICITY, AND THAT THIS PLASTICITY IS REVERSIBLE. WE HAVE IDENTIFIED THE KMT2D HISTONE METHYLTRANSFERASE AND THE KDM1A HISTONE DEMETHYLASE AS HAVING OPPOSING ACTIVITIES IN MODULATING LUMINAL-BASAL PLASTICITY IN ORGANOIDS, CONSISTENT WITH THEIR EFFECTS ON HISTONE H3 LYSINE 4 METHYLATION. MODULATION OF LUMINAL-BASAL PLASTICITY AFFECTS OUTGROWTH OF TUMOR ORGANOIDS IN CULTURE, CONSISTENT WITH A ROLE IN PROGRESSION TO INVASIVE DISEASE, AND CAN RESULT IN IMPROVED RESPONSE TO ENFORTUMAB VEDOTIN, AN ANTIBODY-DRUG CONJUGATE APPROVED FOR TREATMENT OF LOCALLY ADVANCED AND METASTATIC BLADDER CANCER. FINALLY, USING A CELLULAR BARCODING APPROACH FOR LINEAGE TRACING, WE FIND THAT KMT2D MUTATIONS PROMOTE CLONAL EXPANSION IN ORGANOIDS, SUGGESTING THAT CLONAL COMPETITION CAN DRIVE THE SPREAD OF PHENOTYPIC ALTERATIONS DUE TO PLASTICITY DURING TUMOR PROGRESSION. BASED ON OUR PRELIMINARY DATA, WE HYPOTHESIZE THAT LUMINAL-BASAL PLASTICITY AND CLONAL COMPETITION IN HUMAN BLADDER CANCER IS DRIVEN BY EPIGENOMIC REPROGRAMMING. TO INVESTIGATE THIS HYPOTHESIS, WE WILL PURSUE THREE COMPLEMENTARY AIMS THAT INTEGRATE INNOVATIVE IN VITRO, IN VIVO, MOLECULAR, AND BIOINFORMATIC APPROACHES AS FOLLOWS: (1) ANALYSIS OF KMT2D FUNCTION IN MODULATING LUMINAL-BASAL PLASTICITY AND DRUG RESPONSE TO ESTABLISH THE PRECISE ROLES OF KMT2D IN PLASTICITY, INVASIVENESS, AND RESPONSE TO ENFORTUMAB VEDOTIN; (2) ANALYSIS OF CHROMATIN LANDSCAPES IN BLADDER CANCER PLASTICITY AND PROGRESSION TO IDENTIFY CHROMATIN STATES ASSOCIATED WITH LUMINAL- BASAL PHENOTYPIC TRANSITIONS; AND (3) INVESTIGATION OF KMT2D FUNCTION IN CLONAL EVOLUTION TO EXAMINE MECHANISMS BY WHICH KMT2D LOSS PROMOTES CLONAL EXPANSION IN BLADDER CANCER. OVERALL, OUR FINDINGS WILL HAVE A STRONG TRANSLATIONAL IMPACT THROUGH THE IDENTIFICATION OF EPIGENETIC MECHANISMS THAT PROMOTE PLASTICITY AND TUMOR PROGRESSION IN BLADDER CANCER, AND MAY LEAD TO IMPROVED THERAPIES FOR AGGRESSIVE DISEASE.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $477.0k | 7/3/25 | ||
| Not listed | $477.0k | 11/20/24 | ||
| Not listed | $477.0k | 11/20/24 | ||
| Not listed | ($477k) | 11/4/24 | ||
| Not listed | ($477k) | 11/4/24 |